Sanofi Consumer Healthcare IndiaNSE:SANOFICONR +0.18%21 ROE % is 70.63% as of Mar. 2026, which is 6% below its 10-year median of 75.32. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 935 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks better than 97.54% on this metric.
NSE:SANOFICONR'
s ROE % Range Over the Past 10 Years
Min: 73.09 Med: 75.32 Max: 84.65
Current: 84.65
During the past 3 years, Sanofi Consumer Healthcare India's highest ROE % was 84.65%. The lowest was 73.09%. And the median was 75.32%.
NSE:SANOFICONR's ROE % is ranked better than 97.54% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs NSE:SANOFICONR: 84.65
Sanofi Consumer Healthcare India (NSE:SANOFICONR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Sanofi Consumer Healthcare India ROE % Related Terms
Sanofi Consumer Healthcare India ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SANOFICONR vs LLY, JNJ, ABBV: ROE % Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's ROE % distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a ROE % of 70.63% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sanofi Consumer Healthcare India and its competitors. This is near median its historical median of 75.32. Over the past decade, Sanofi Consumer Healthcare India's ROE % has ranged from 73.09 to 84.65. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #23 out of 935 companies in the Drug Manufacturers industry, placing it in the top 2.5%.
Is Sanofi Consumer Healthcare India's ROE % too high?
Sanofi Consumer Healthcare India's current ROE % of 70.63% is near median its 10-year median of 75.32. Over the past 10 years, this metric has ranged from a low of 73.09 to a high of 84.65. The Drug Manufacturers industry median ROE % is 6.00. Sanofi Consumer Healthcare India's value of 70.63% is 1077.2% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #23 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #23 out of 935 companies for ROE %. This places Sanofi Consumer Healthcare India in the top 3% of its industry — outperforming the majority of peers. The industry median ROE % is 6.00. Sanofi Consumer Healthcare India's value of 70.63% is 1077.2% above this benchmark. Historically, Sanofi Consumer Healthcare India's own ROE % has ranged from 73.09 to 84.65 over the past decade. While the company's 10-year median is 75.32 vs. the industry median of 6.00, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current ROE % of 70.63% is 1077.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sanofi Consumer Healthcare India and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current ROE % is 70.63%, which is near median its own 10-year median of 75.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current ROE % of 70.63%. The current ROE % is 70.63%, which is near median its 10-year median of 75.32 and 1077.2% above the Drug Manufacturers industry median of 6.00. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current ROE % is 70.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Business Description
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score
Get the complete analysis for NSE:SANOFICONR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
